vTv Therapeutics Inc. VTVT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
36/100
Developing

Ranked against 712 peers in Biotechnology

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a … Full VTVT analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.88), providing operational cushion.

Key risks

  • Below-Peer Operating Efficiency Operating margin at 30.7th percentile indicates below-peer efficiency.
  • Elevated Debt Risk Debt serviceability is weak (score 0.05), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
40
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where VTVT ranks in Biotechnology

vTv Therapeutics Inc. ranks #428 of 713 scored companies in Biotechnology by moat score — the top 60%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
424 ProKidney Corp. PROK 36/100 Developing
425 Syros Pharmaceuticals, Inc. SYRS 36/100 Developing
426 Arcellx, Inc. ACLX 36/100 Developing
427 Citius Pharmaceuticals, Inc. CTXR 36/100 Developing
428 vTv Therapeutics Inc. VTVT 36/100 Developing
429 Windtree Therapeutics, Inc. WINT 36/100 Developing
430 Verastem, Inc. VSTM 36/100 Developing
431 Immunome, Inc. IMNM 36/100 Developing
432 Vaccinex, Inc. VCNX 36/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How VTVT scores on the Corporate Default defenses

Pricing Power

Score 40 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 26 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 38 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 27 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 35 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 48 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding VTVT's moat

What is vTv Therapeutics Inc.'s moat score?

vTv Therapeutics Inc. (VTVT) scores 36 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #428 of 713 scored companies in Biotechnology, the top 60%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (48/100) and its weakest is Cost Advantage (26/100).

How does vTv Therapeutics Inc. compare with other Biotechnology companies?

vTv Therapeutics Inc. ranks #428 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Citius Pharmaceuticals, Inc. (CTXR) at 36 just above it and Windtree Therapeutics, Inc. (WINT) at 36 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is vTv Therapeutics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for vTv Therapeutics Inc.?

The Corporate Default template measures 6 defenses, and VTVT scores: Pricing Power (40), Cost Advantage (26), Customer Stickiness (38), Capital Efficiency (27), Resilience (35), Scale & Market Position (48). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000